Stada Out, But Emerging Markets Move Up Teva's Wish List

Israel's Teva Pharmaceutical Industries has moved to end speculation that it is eying up an acquisition of Germany's Stada Arzneimittel. Teva's North American CEO William Marth stated 'I currently don't think that would be a good acquisition for us', when quizzed at the Generic Pharmaceutical Association (GPhA) Annual Policy Conference in

To read the full article, please choose one of the following options: